Trials / Completed
CompletedNCT01326858
Safety and Comfort of AL-4943A Ophthalmic Solution
A Randomized, Double-Masked, Crossover Study to Evaluate the Safety and Comfort of AL-4943A Ophthalmic Solution, 0.7%
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Alcon Research · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the ocular comfort and safety of olopatadine hydrochloride opthalmic solution. 0.7%.
Detailed description
In this 3-treatment, 3-period, 6-sequence crossover study, each subject will receive all 3 products in randomized order, 1 product at a time, with a washout period of 24 hours between treatment periods. Following instillation of study medication, subjects will complete a 3-minute discomfort profile.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olopatadine hydrochloride ophthalmic solution, 0.7% | Treatment A |
| DRUG | Olopatadine hydrochloride ophthalmic solution vehicle | Treatment B, inactive ingredients used as placebo |
| DRUG | Ketotifen fumarate ophthalmic solution, 0.025% | Treatment C |
Timeline
- Start date
- 2011-04-01
- Primary completion
- 2011-06-01
- Completion
- 2011-06-01
- First posted
- 2011-03-31
- Last updated
- 2015-03-03
Source: ClinicalTrials.gov record NCT01326858. Inclusion in this directory is not an endorsement.